Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Rhinomed attracts funding to accelerate growth of its anti-snoring device

Rhinomed Ltd (ASX:RNO) has completed a $3.6 million share placement to institutional and sophisticated investors at $0.15 per share.

Rhinomed takes its nasal breathing product into the Taiwanese market

Rhinomed Ltd (ASX:RNO) has signed a distribution agreement with Brojaw Inc., to begin distributing its snoring and nasal breathing product Mute into the Taiwanese market.

Rhinomed bags $2.1M to expand breathing technology solutions

Rhinomed (ASX:RNO) has undertaken a $2.1 million private placement to two U.S. based sophisticated investor groups to fund its retail distribution expansion.

Rhinomed to lift cash balance

Rhinomed (ASX:RNO) has been granted a trading halt by the ASX, pending details of a capital raising.

Rhinomed And The Team Up To Transform Australian Sleep Market

2016-12-07 devicespace
MELBOURNE, Australia, Dec. 7, 2016 /PRNewswire/ -- Australian innovator Rhinomed (ASX:RNO) is seeking to transform the way consumers view sleep by teaming up with sleep giant The Linde Group through its subsidiary BOC Limited.

Mute Makes U.S. Debut in Select Walgreens and Duane Reade Stores

2016-05-31 prnewswire
MELBOURNE, Australia, May 31, 2016 /PRNewswire/ -- Rhinomed LTD (ASX:RNO), an Australian nasal and respiratory technology company, is pleased to announce the U.S. debut of its Mute snoring and sleep technology. All four Mute packs (trial, small, medium and large) are now available in select Walgreens and Duane Reade stores across the U.S., including approximately 100 of the chain's locations throughout Manhattan, New York.

Sleep Apnea Clinical Trial Update